MIL62
MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
Species Reactivity
Human
IC50 & Target
CD20/MS4A1
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Shi Y, et al. Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial. EClinicalMedicine. 2024 Jun 20;73:102702. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
MIL62 Related Classifications
HY-P991514 Related Classifications
Powered by Bioz